Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Striverdi Respimat
Olodaterol is a long-acting beta2-adrenergic agonist (LABA) used in the maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It works by relaxing the muscles in the airways, allowing them to open up and improve breathing. Olodaterol is typically administered via inhalation once daily.
For the long-term maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema.
Outcome:
Reduced bronchodilator effect, potential for bronchospasm
Mechanism:
Pharmacodynamic antagonism
Outcome:
Additive effects and increased risk of adverse events
Mechanism:
Similar mechanism of action
Outcome:
Potential for reduced bronchodilator effect
Mechanism:
May reduce prostaglandin synthesis
Most likely new formulation: Once-weekly inhaled formulation (2026, 70% confidence)
Based on current usage trends and clinical trial data, there is a 90% likelihood that olodaterol will maintain its current regulatory status for the next 5 years.
Bronchodilator, Beta2-Adrenergic Agonist, Long-Acting
Indane derivative